20cm Express | From "Burning Money" to "Profiting," the Guotai (589720) Science and Innovation Drug ETF surged over 2% during trading, as the global competitiveness of domestically innovative drugs significantly improves.

From “burning money” to “making money,” on April 2, the Guotai CSI Science and Innovation Innovative Drug ETF (589720) surged more than 2% intraday, with China’s domestic innovative drug industry showing significantly enhanced global competitiveness.

According to Galaxy Securities, the pharmaceutical and biological sciences industry is undergoing a transition from “integration of imitation and innovation” to “original innovation and high-quality development.” The “15th Five-Year Plan” period (i.e., the 15th Five-Year Plan and beyond) first listed biopharmaceuticals as a national “emerging pillar industry,” further提升 the strategic positioning. Through strong policy support across the entire chain, on the one hand, the number of approved domestically developed Class 1 new drugs reached a record high, while the cross-border BD overseas deal amounts and the size of initial payments increased, indicating significantly enhanced global competitiveness; on the other hand, in life sciences, upstream segments and high-end medical devices are accelerating domestic substitution to address the “bottleneck” problem, while also deepening the inheritance and innovation of traditional Chinese medicine and strictly regulating re-evaluations to reshape the market landscape. Coupled with AI technology fully empowering R&D, diagnosis, and service scenarios, it ultimately builds a modern pharmaceutical and healthcare industrial system that is independently controllable and has global influence, accelerating the shift from a “pharmaceutical manufacturing power” to a “pharmaceutical manufacturing powerhouse.”

The Guotai CSI Science and Innovation Innovative Drug ETF (589720) tracks the CSI Science and Innovation Innovative Drug Index (950161). The index has a daily price fluctuation limit of 20%. The index focuses on the R&D of new drugs driven by technological innovation. Constituent stocks include listed companies engaged in research, development, and manufacturing of innovative drugs. The index emphasizes the high-growth potential and innovativeness of the biopharmaceutical industry, aiming to reflect the performance of relevant companies in new drug R&D and their market value.

Risk warning: The mention of individual stocks is only for industry event analysis and does not constitute any recommendation or investment advice regarding any individual stock. Indexes’ short-term gains and losses are for reference only and do not represent any commitment or guarantee regarding the future performance of the index, nor do they constitute any commitment or guarantee regarding fund performance. Views may be adjusted with changes in market conditions and do not constitute investment advice or commitments. Since the mentioned fund’s risk-return characteristics differ from one another, investors are kindly reminded to carefully read the fund legal documents, fully understand the product elements, risk levels, and the principles of profit distribution, choose products that match their own risk tolerance, and invest cautiously. For details on fund fees, please refer to the legal documents.

Daily Economic News

(Editor: Dong Pingping)

     【Disclaimer】This article only represents the author’s own views and is not related to Hexun. The Hexun website maintains neutrality toward the statements and judgments in the text, and provides no express or implied guarantee regarding the accuracy, reliability, or completeness of any of the content. Readers are advised to use it for reference only and bear all responsibility themselves. Email: news_center@staff.hexun.com

Report